This article is more than 5 years old. Information may no longer be current.

FDA grants priority review to Lucentis for diabetic retinopathy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has granted priority review of Lucentis for the treatment of diabetic retinopathy, according to a Genentech press release.

The company’s supplemental Biologics License Application was submitted on Aug. 7, 2014, based on results from the RISE and RIDE phase 3 trials, and an action date of Feb. 6, 2015, has been scheduled.

If approved, Lucentis (ranibizumab) could be the first eye medication made available to patients with diabetic retinopathy, according to the release.

The injection was the first FDA-approved agent for treatment of diabetic macular edema in August 2012.